Ackman Shoots Down Idea of Valeant (VRX) Unloading Bausch & Lomb

Pershing Square's Bill Ackman, speaking on CNBC late Thursday, said that Valeant Pharma (NYSE: VRX) isn't going to sell its Bausch & Lomb unit.

It's a core asset. We're only considering selling non-core assets, Ackman, who was recently appointed to Valeant's board, commented.

Ackman recently said on Pershing Square's Q1 conference call that Valeant's board was working expeditiously to find a replacement CEO for outgoing Mike Pearson, but that Pearson was doing a terrific job in the interim. Ackman believes a new CEO could be appointed within weeks, not months.

Shares of Valeant are indicated for a higher open Friday.

You May Also Be Interested In

• Regal Rexnord Corporation (RRX) Mentioned as Long at Kerrisdale
• Enphase Energy (ENPH), SolarEdge Technologies (SEDG) Gain on Chatter of Ban Foreign Energy Inverters
• Nano Nuclear In Early Investment Talks From UAE Firm - Semafor